Nektar says Phase 3 ZENITH AD trial for rezpegaldesleukin expands into treatment-experienced patients
Bitget2026/10/01 11:31- Nektar Therapeutics presented 1-year Phase 2b data for rezpegaldesleukin at EADV Congress 2026 in Vienna.
- Alopecia areata results showed durable benefit after stopping treatment, with some patients continuing to improve during follow-up.
- Atopic dermatitis maintenance data indicated sustained disease control on less frequent dosing, with additional patients improving over time.
- Phase 3 plans advanced, with a new atopic dermatitis trial started and an alopecia areata pivotal study slated for early 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UK names 6 banks to lead first digitally native government bond
Altaris Completes Acquisition of Simulations Plus
02:57 PM EDT, 10/06/2026 (MT Newswires) -- Simulations Plus (SLP) said Tuesday that affiliates of Altaris have completed the acquisition of the company. The transaction price was $375 million, with each Simulations shareholder receiving $18.50 in cash per share, according to an earlier statement. As a result of the acquisition, Simulations said it has become a privately held company and its common stock will no longer trade on the Nasdaq Global Select Market.
Ondo Finance brings pre-IPO AI exposure on-chain — But there’s a catch
Philippines: One more BSP hike expected in October - Standard Chartered
Crypto prices
More
